---
title: "LB Pharmaceuticals prices USD 150 million private placement at USD 34.94 per share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294206557.md"
description: "LB Pharmaceuticals priced a USD 150 million private placement at USD 34.94 per share, involving 3,577,560 common shares and pre-funded warrants for up to 715,513 additional shares. Proceeds will fund the expansion of LB-102 into new indications, working capital, and general corporate purposes. The closing is expected around July 30, 2026."
datetime: "2026-07-29T12:20:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294206557.md)
  - [en](https://longbridge.com/en/news/294206557.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294206557.md)
---

# LB Pharmaceuticals prices USD 150 million private placement at USD 34.94 per share

-   LB Pharmaceuticals priced a USD 150 million private placement of common stock and pre-funded warrants with institutional investors. \* Deal includes 3,577,560 common shares at USD 34.94 each. \* Also selling pre-funded warrants for up to 715,513 shares at USD 34.9399 each, with a USD 0.0001 exercise price. \* Closing expected around July 30, 2026, subject to customary conditions. \* Proceeds earmarked for expanding LB-102 into new indications, working capital, general corporate purposes. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [LBRX.US](https://longbridge.com/en/quote/LBRX.US.md)

## Related News & Research

- [LB Pharmaceuticals releases update on NOVA-2 Phase 3 schizophrenia trial timeline](https://longbridge.com/en/news/293470551.md)
- [LB Pharmaceuticals: Buy Rating Reaffirmed on LB-102 Clinical Momentum and Regulatory Progress; $45 Price Target Maintained](https://longbridge.com/en/news/293644868.md)
- [NanoViricides issues warrants exercisable at US$1.75 in US$3.8 million registered direct offering](https://longbridge.com/en/news/294342376.md)
- [Vyne Therapeutics issues pre-funded warrants for 133,290 shares in stock exchange deal](https://longbridge.com/en/news/294409414.md)
- [Inhibikase swaps 18,030,000 shares for RA Capital pre-funded warrant in unregistered offering](https://longbridge.com/en/news/294255122.md)